A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1
150
about 4.7 years
18+
19 sites in AR, CA, CO +10
What this study is about
This trial is testing a treatment called NKT3964 in adults with advanced or metastatic solid tumors. The goal is to see if this treatment is safe, how well it works, and what dose might be best.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take NKT3964
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants with Dose Limiting Toxicity (DLT) events, Objective Response Rate (ORR)
Secondary: Apparent clearance (CL/F) of NKT3964, Disease control rate, Duration of Response (DOR), Half-life (t1/2) of NKT3964, Maximum observed plasma concentration (Cmax) of NKT3964 with and without a high-fat and/or low-fat meal, Number of Participants with Adverse Events, Overall Survival (OS), Progression-free survival (PFS)
Oncology